(Date:11/24/2009)...Newswire-FirstCall/--Sigma-AldrichCorporation(Nasd...onTuesday,December1stat1:45PMGMTinLondon,7:45AMUS/...tovertheInternetavailableat http://inve s tor.s...t"icontoaccessthisfile. ,, AboutSigma-Aldrich...logycompany.Itschemicalandbiochemicalproductsandki...
(Date:11/24/2009)...v.24/PRNewswire-FirstCall/--NeurogesX,Inc.(Nasdaq:...ngandcommercializingnovelpainmanagementtherapies,a...xecutiveOfficer,isscheduledtopresentatthe21stAnnua...1-2,2009atTheNewYorkPalaceHotelinNewYork,NewYork. ...Officer,willbeavailabletorespondtoquestionsduringt...
(Date:11/24/2009)...pointhasbeenmetforpatientswithadvanced-stage,orrec...PRNewswire-FirstCall/-AEternaZentarisInc.(NASDAQ: ...calcompanyfocusedonendocrinetherapyandoncology,tod...hitstargetedcytotoxicpeptideconjugate,AEZS-108(for...metrialcancer.Inapersonalizedhealthcareapproach,th...
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--GenomicHealth,Inc.(...Health,sExecutiveChairman,willpresentatthe21stAnnu...uesday,December1,2009at10:00a.m.ET. ,, Toaccess...tion,visittheInvestorRelationssectionofGenomicHeal...leaseconnecttothewebsiteatleast15minutespriortothe...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Genomic Health to Present at Piper Jaffray Health Care Conference 2... reports full year operating income of $856,000, ...n (Pink Sheets: CGCP), a leading developer of surg...ving procedures, today reported,financial results ...ber 31,2007., Sales in the fourth quarter of 2007... year fourth quarter sales of $3,664,000. During t...
...NCISCO, March 25 Medivation, Inc.,(Nasdaq: MDVN ...nson, Ph.D.,to vice president, regulatory and qual...inical development, and Joyce Mordenti, Ph.D., to ...nter Phase 3 development for our lead product cand...dvance our clinical programs," said,Lynn Seely, M....
...INO, Calif., March 25 Epeius Biotechnologies,Corp...o. 7,347,998 for,Targeted Gene Delivery in vivo. T...ty protection for the platform of highly advanced,...anti-cancer agent,Rexin-G. Administered clinically...targeted gene delivery system enables Rexin-G to s...
Other Biology Technology:Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 2Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 3Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 4Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 5Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 6Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results 7Medivation Announces Senior Management Promotions 2Medivation Announces Senior Management Promotions 3Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo 2Film Exposure Folders from Upstate
Rabbit Anti-SUR1 Polyclonal Antibody, Unconjugated from Abcam
TenderTouch™ from RNAture, Inc.
T7Select Biopanning Kit from Novagen
Biology Products: